169045-01-6

Basic information

• Product Name: 7-AMINO-4-BROMOISOINDOLIN-1-ONE
• Synonyms: 7-AMINO-4-BROMOISOINDOLIN-1-ONE;7-Amino-4-bromo-2,3-dihydro-isoindol-1-one
• CAS NO: 169045-01-6
• Molecular Formula: C₈H₇BrN₂O
• Molecular Weight: 227.06
• Mol File: 169045-01-6.mol

Chemical Properties

• Boiling Point: 524.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.753±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: DMSO (Slightly, Sonicated), Tetrahydrofuran (Very Slightly)
• PKA: 13.56±0.20(Predicted)
• CAS DataBase Reference: 7-AMINO-4-BROMOISOINDOLIN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-AMINO-4-BROMOISOINDOLIN-1-ONE(169045-01-6)
• EPA Substance Registry System: 7-AMINO-4-BROMOISOINDOLIN-1-ONE(169045-01-6)

Safety Data

• Hazardous Substances Data: 169045-01-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
7-Amino-4-bromoisoindolin-1-one is used as a key intermediate in the synthesis of pharmaceuticals for its potential role in the development of new drugs. Its unique structure allows it to be a versatile component in creating various medicinal compounds.
Used in Organic Chemistry Research:
In the field of organic chemistry, 7-Amino-4-bromoisoindolin-1-one is used as a reagent in chemical processes. Its properties make it valuable for studying and advancing the understanding of organic reactions and mechanisms.
Used in Medicinal Chemistry Research:
7-Amino-4-bromoisoindolin-1-one is utilized in medicinal chemistry research for exploring its potential in creating new therapeutic agents. Its unique attributes contribute to the discovery and optimization of drug candidates for various medical applications.

Upstream product

• 866767-06-8 4-amino-7-bromoisoindoline-1,3-dione 
• 2518-24-3 3-aminophthalimide 
• 169044-98-8 7-amino-2,3-dihydro-1H-isoindol-1-one 
• 337536-14-8 methyl 3-bromo-2-(bromomethyl)benzoate 
• 99548-54-6 methyl 3-bromo-2-methylbenzoate 
• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 765948-99-0 4-bromo-7-nitroisoindolin-1-one 
• 337536-15-9 4-bromo-2,3-dihydro-isoindol-1-one 
• 866767-11-5 7-amino-4-bromo-3-hydroxyisoindolinone 

Relevant articles and documents

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

Cdc2-like kinases (CLKs) represent a family of serine-threonine kinases involved in the regulation of splicing by phosphorylation of SR-proteins and other splicing factors. Although compounds acting against CLKs have been described, only a few show select

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

HETEROCYCLIC COMPOUND AS CSF-1R INHIBITOR AND USE THEREOF

The present invention relates to a class of isoindolinone derivatives and use thereof in the preparation of a medicament for treating diseases associated with a novel colony stimulating factor 1 receptor (CSF-1R) inhibitor. In particular, the present invention relates to a compound of formula (I) and a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

JAK INHIBITOR

A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) {wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.